Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates

Group 1 - Jazz Pharmaceuticals reported quarterly earnings of $6.60 per share, exceeding the Zacks Consensus Estimate of $5.79 per share, and up from $5.02 per share a year ago, representing an earnings surprise of 13.99% [1] - The company achieved revenues of $1.09 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 2.57%, and an increase from $1.01 billion year-over-year [2] - Over the last four quarters, Jazz has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Group 2 - The stock has gained approximately 11% since the beginning of the year, outperforming the S&P 500's gain of 1.7% [3] - The current consensus EPS estimate for the upcoming quarter is $4.34 on revenues of $981.29 million, and for the current fiscal year, it is $22.11 on revenues of $4.33 billion [7] - The Medical - Biomedical and Genetics industry, to which Jazz belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook [8]